228 related articles for article (PubMed ID: 32513774)
1. The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.
Liu H; Paddock MN; Wang H; Murphy CJ; Geck RC; Navarro AJ; Wulf GM; Elemento O; Haucke V; Cantley LC; Toker A
Cancer Discov; 2020 Aug; 10(8):1226-1239. PubMed ID: 32513774
[TBL] [Abstract][Full Text] [Related]
2. INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.
Reed DE; Shokat KM
Mol Cancer Res; 2017 Jun; 15(6):765-775. PubMed ID: 28196852
[TBL] [Abstract][Full Text] [Related]
3. INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
Sun Y; Ding H; Liu X; Li X; Li L
Tumour Biol; 2014 May; 35(5):4469-77. PubMed ID: 24420152
[TBL] [Abstract][Full Text] [Related]
4. INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer.
Rodgers SJ; Ooms LM; Oorschot VMJ; Schittenhelm RB; Nguyen EV; Hamila SA; Rynkiewicz N; Gurung R; Eramo MJ; Sriratana A; Fedele CG; Caramia F; Loi S; Kerr G; Abud HE; Ramm G; Papa A; Ellisdon AM; Daly RJ; McLean CA; Mitchell CA
Nat Commun; 2021 May; 12(1):3140. PubMed ID: 34035258
[TBL] [Abstract][Full Text] [Related]
5. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
6. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
Fedele CG; Ooms LM; Ho M; Vieusseux J; O'Toole SA; Millar EK; Lopez-Knowles E; Sriratana A; Gurung R; Baglietto L; Giles GG; Bailey CG; Rasko JE; Shields BJ; Price JT; Majerus PW; Sutherland RL; Tiganis T; McLean CA; Mitchell CA
Proc Natl Acad Sci U S A; 2010 Dec; 107(51):22231-6. PubMed ID: 21127264
[TBL] [Abstract][Full Text] [Related]
7. The INPP4B paradox: Like PTEN, but different.
Hamila SA; Ooms LM; Rodgers SJ; Mitchell CA
Adv Biol Regul; 2021 Dec; 82():100817. PubMed ID: 34216856
[TBL] [Abstract][Full Text] [Related]
8. Phosphoinositide signaling in cancer: INPP4B Akt(s) out.
Woolley JF; Dzneladze I; Salmena L
Trends Mol Med; 2015 Sep; 21(9):530-2. PubMed ID: 26150301
[TBL] [Abstract][Full Text] [Related]
9. A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms.
Perez-Lorenzo R; Gill KZ; Shen CH; Zhao FX; Zheng B; Schulze HJ; Silvers DN; Brunner G; Horst BA
J Invest Dermatol; 2014 May; 134(5):1359-1368. PubMed ID: 24288008
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.
Li Chew C; Lunardi A; Gulluni F; Ruan DT; Chen M; Salmena L; Nishino M; Papa A; Ng C; Fung J; Clohessy JG; Sasaki J; Sasaki T; Bronson RT; Hirsch E; Pandolfi PP
Cancer Discov; 2015 Jul; 5(7):740-51. PubMed ID: 25883022
[TBL] [Abstract][Full Text] [Related]
11. Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer.
Tokunaga E; Yamashita N; Kitao H; Tanaka K; Taketani K; Inoue Y; Saeki H; Oki E; Oda Y; Maehara Y
Breast; 2016 Feb; 25():62-8. PubMed ID: 26577950
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Nair A; Chung HC; Sun T; Tyagi S; Dobrolecki LE; Dominguez-Vidana R; Kurley SJ; Orellana M; Renwick A; Henke DM; Katsonis P; Schmitt E; Chan DW; Li H; Mao S; Petrovic I; Creighton CJ; Gutierrez C; Dubrulle J; Stossi F; Tyner JW; Lichtarge O; Lin CY; Zhang B; Scott KL; Hilsenbeck SG; Sun J; Yu X; Osborne CK; Schiff R; Christensen JG; Shields DJ; Rimawi MF; Ellis MJ; Shaw CA; Lewis MT; Westbrook TF
Nat Med; 2018 May; 24(4):505-511. PubMed ID: 29578538
[TBL] [Abstract][Full Text] [Related]
13. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
14. INPP4B Is a PtdIns(3,4,5)P3 Phosphatase That Can Act as a Tumor Suppressor.
Kofuji S; Kimura H; Nakanishi H; Nanjo H; Takasuga S; Liu H; Eguchi S; Nakamura R; Itoh R; Ueno N; Asanuma K; Huang M; Koizumi A; Habuchi T; Yamazaki M; Suzuki A; Sasaki J; Sasaki T
Cancer Discov; 2015 Jul; 5(7):730-9. PubMed ID: 25883023
[TBL] [Abstract][Full Text] [Related]
15. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
[TBL] [Abstract][Full Text] [Related]
16. Determinants of the tumor suppressor INPP4B protein and lipid phosphatase activities.
Lopez SM; Hodgson MC; Packianathan C; Bingol-Ozakpinar O; Uras F; Rosen BP; Agoulnik IU
Biochem Biophys Res Commun; 2013 Oct; 440(2):277-82. PubMed ID: 24070612
[TBL] [Abstract][Full Text] [Related]
17. Loss of tumor suppressor inositol polyphosphate 4-phosphatase type B impairs DNA double-strand break repair by destabilization of DNA tethering protein Rad50.
Sun Y; Ning X; Fan J; Hu J; Jiang Y; Hu Z; Paulo JA; Liu J; Qiu X; Xu H; Fu S; Gygi SP; Zhang J; Zhou C
Cell Death Dis; 2020 Apr; 11(4):292. PubMed ID: 32341333
[TBL] [Abstract][Full Text] [Related]
18. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
19. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
20. Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity.
Zhang M; Suarez E; Vasquez JL; Nathanson L; Peterson LE; Rajapakshe K; Basil P; Weigel NL; Coarfa C; Agoulnik IU
Oncogene; 2019 Feb; 38(7):1121-1135. PubMed ID: 30228349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
